Government launches 7th National Formulary of India 2026 and announces Biovigilance Programme to widen India’s patient-safety net

Union Minister of State for Health & Family Welfare and Chemicals & Fertilizers, Smt. Anupriya Patel, today launched the 7th Edition of the National Formulary of India (NFI), the Guidance Document for Hospitals in India for Safety Monitoring and Reporting of Medical Device-Related Adverse Events, and the ADR-PvPI 2.0 Mobile App for iOS users at the 6th National Pharmacovigilance Week programme organised by the Indian Pharmacopoeia Commission (IPC) at Dr. Ambedkar International Centre, New Delhi. The 7th Edition of the NFI has also been made available digitally through NFI Online.

Biovigilance Programme of India

In a significant expansion of India’s patient-safety framework, Government launched the Biovigilance Programme of India. 

Under the programme, Indian Pharmacopoeia Commission (IPC) will play a lead role in strengthening the reporting, assessment, monitoring and prevention of adverse events associated with medicines and biological products used in organ and tissue transplantation, including products administered to donors and recipients.

Together, the pharmacovigilance, materiovigilance and biovigilance initiatives will strengthen safety monitoring across medicines, medical devices and transplant procedures.

About National Formulary of India ( NFI ) 2026

The National Formulary of India, published periodically by IPC since 2009, is a guidance document for healthcare professionals aimed at promoting the rational and safe use of medicines.

The NFI 2026 comprises 34 chapters, 20 appendices and 653 drugs, including 42 fixed-dose combinations and 30 immunologicals. Drug monographs have been revised to align with the National List of Essential Medicines (NLEM) and National Health Programmes.

In addition to the print edition, the NFI is available digitally and provides access to important links relating to National Health Programmes, immunisation schedules, Jan Aushadhi, safe disposal of unused or expired pharmaceutical products and other authoritative regulatory resources.

PIB

Comments

Popular posts from this blog

Rural Local Bodies in Kerala Receive Over ₹260 Crores as First Instalment of XV Finance Commission Grants

ISRO developing semi-cryogenic engine working on LOX Kerosene propellant